NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis
USA - NYSE:NMR - US65535H2085 - ADR
6.73 USD
-0.42 (-5.87%)
6.79 USD
+0.06 (+0.89%)
Overall NMR gets a fundamental rating of 3 out of 10. We evaluated NMR against 238 industry peers in the Capital Markets industry. NMR has a bad profitability rating. Also its financial health evaluation is rather negative. NMR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NMR was profitable.
In the past year NMR has reported a negative cash flow from operations.
In the past 5 years NMR has always been profitable.
In multiple years NMR reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of NMR (0.60%) is worse than 70.17% of its industry peers.
NMR has a Return On Equity (9.82%) which is in line with its industry peers.
NMR has a Return On Invested Capital of 0.63%. This is in the lower half of the industry: NMR underperforms 70.59% of its industry peers.
NMR had an Average Return On Invested Capital over the past 3 years of 0.42%. This is significantly below the industry average of 7.64%.
The 3 year average ROIC (0.42%) for NMR is below the current ROIC(0.63%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROIC | 0.63% |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
1.3 Margins
With a Profit Margin value of 7.19%, NMR is not doing good in the industry: 63.87% of the companies in the same industry are doing better.
In the last couple of years the Profit Margin of NMR has declined.
Looking at the Operating Margin, with a value of 9.96%, NMR is doing worse than 67.65% of the companies in the same industry.
NMR's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 39.95%, NMR is in line with its industry, outperforming 40.34% of the companies in the same industry.
In the last couple of years the Gross Margin of NMR has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% |
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
2. Health
2.1 Basic Checks
Compared to 1 year ago, NMR has less shares outstanding
The number of shares outstanding for NMR has been reduced compared to 5 years ago.
The debt/assets ratio for NMR has been reduced compared to a year ago.
2.2 Solvency
NMR has an Altman-Z score of -0.27. This is a bad value and indicates that NMR is not financially healthy and even has some risk of bankruptcy.
NMR has a Altman-Z score of -0.27. This is in the lower half of the industry: NMR underperforms 77.73% of its industry peers.
A Debt/Equity ratio of 10.44 is on the high side and indicates that NMR has dependencies on debt financing.
With a Debt to Equity ratio value of 10.44, NMR is not doing good in the industry: 89.50% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.27 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.22 indicates that NMR may have some problems paying its short term obligations.
NMR's Current ratio of 0.22 is on the low side compared to the rest of the industry. NMR is outperformed by 87.39% of its industry peers.
NMR has a Quick Ratio of 0.22. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.22, NMR is doing worse than 86.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.22 | ||
| Quick Ratio | 0.22 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 79.28% over the past year.
The Earnings Per Share has been growing by 10.96% on average over the past years. This is quite good.
NMR shows a small growth in Revenue. In the last year, the Revenue has grown by 4.32%.
The Revenue has been growing by 19.39% on average over the past years. This is quite good.
EPS 1Y (TTM)79.28%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%62.38%
Revenue 1Y (TTM)4.32%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-4.36%
3.2 Future
The Earnings Per Share is expected to grow by 1.45% on average over the next years.
The Revenue is expected to decrease by -6.34% on average over the next years.
EPS Next Y-2.38%
EPS Next 2Y0.42%
EPS Next 3Y1.45%
EPS Next 5YN/A
Revenue Next Year-22.11%
Revenue Next 2Y-10.98%
Revenue Next 3Y-6.34%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 7.65 indicates a rather cheap valuation of NMR.
Based on the Price/Earnings ratio, NMR is valued cheaply inside the industry as 80.25% of the companies are valued more expensively.
NMR's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.02.
NMR is valuated reasonably with a Price/Forward Earnings ratio of 8.53.
NMR's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. NMR is cheaper than 76.47% of the companies in the same industry.
NMR is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.57, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.65 | ||
| Fwd PE | 8.53 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NMR indicates a somewhat cheap valuation: NMR is cheaper than 68.49% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 22.41 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)0.7
EPS Next 2Y0.42%
EPS Next 3Y1.45%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.34%, NMR is a good candidate for dividend investing.
NMR's Dividend Yield is comparable with the industry average which is at 8.40.
NMR's Dividend Yield is rather good when compared to the S&P500 average which is at 2.43.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.34% |
5.2 History
The dividend of NMR is nicely growing with an annual growth rate of 15.59%!
NMR has paid a dividend for at least 10 years, which is a reliable track record.
NMR has decreased its dividend in the last 3 years.
Dividend Growth(5Y)15.59%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
33.03% of the earnings are spent on dividend by NMR. This is a low number and sustainable payout ratio.
The dividend of NMR is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP33.03%
EPS Next 2Y0.42%
EPS Next 3Y1.45%
6.73
-0.42 (-5.87%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners41.49%
Inst Owner Change-0.03%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.74B
Analysts73.33
Price Target7.73 (14.86%)
Short Float %0.06%
Short Ratio3.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.34% |
Yearly Dividend0.26
Dividend Growth(5Y)15.59%
DP33.03%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.99%
Min EPS beat(2)-10.21%
Max EPS beat(2)58.19%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.65%
PT rev (3m)6.86%
EPS NQ rev (1m)-0.19%
EPS NQ rev (3m)177.57%
EPS NY rev (1m)-0.21%
EPS NY rev (3m)3.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1%
Revenue NY rev (3m)-19.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.65 | ||
| Fwd PE | 8.53 | ||
| P/S | 0.64 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.87 | ||
| P/tB | 0.89 | ||
| EV/EBITDA | 22.41 |
EPS(TTM)0.88
EY13.08%
EPS(NY)0.79
Fwd EY11.72%
FCF(TTM)-3.46
FCFYN/A
OCF(TTM)-1.52
OCFYN/A
SpS10.59
BVpS7.76
TBVpS7.59
PEG (NY)N/A
PEG (5Y)0.7
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROCE | 1.65% | ||
| ROIC | 0.63% | ||
| ROICexc | 0.69% | ||
| ROICexgc | 0.7% | ||
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% | ||
| FCFM | N/A |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
ROICexc(3y)0.46%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.09%
ROCE(5y)1.09%
ROICexcg growth 3Y16.87%
ROICexcg growth 5Y8.04%
ROICexc growth 3Y16.9%
ROICexc growth 5Y8.08%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-Score6
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 67.92 | ||
| Cap/Depr | 1410.99% | ||
| Cap/Sales | 18.37% | ||
| Interest Coverage | 0.16 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.22 | ||
| Quick Ratio | 0.22 | ||
| Altman-Z | -0.27 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.28%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%62.38%
EPS Next Y-2.38%
EPS Next 2Y0.42%
EPS Next 3Y1.45%
EPS Next 5YN/A
Revenue 1Y (TTM)4.32%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-4.36%
Revenue Next Year-22.11%
Revenue Next 2Y-10.98%
Revenue Next 3Y-6.34%
Revenue Next 5YN/A
EBIT growth 1Y72.34%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year23564.2%
EBIT Next 3Y523.02%
EBIT Next 5YN/A
FCF growth 1Y-122.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-883.38%
OCF growth 3YN/A
OCF growth 5YN/A